Sleep has remained the focus of numerous studies recently, including a new report from the University of California, San Francisco that suggests a lack of sleep may reduce the efficacy of vaccines.
As reported by TIME, authors of the study claim this is the first “real-world” look at the connection between the amount of sleep we get and our immune response to vaccines.
The study took place outside of a traditional lab setting and instead tracked participants in their ‘day-to-day’ sleep patterns outside of a controlled environment. Participants were middle-aged and researchers studied how their bodies reacted to a ‘standard three-dose hepatitis B’ vaccine.
Findings revealed that those who got less than six hours of sleep a night on average fared much worse than those who slept more when it came to antibody response. In fact, they were found 11.5 times more likely to be unprotected by an immunization.
Lead author Dr. Aric Prather pointed out that this study shows concrete evidence of a connection between inadequate sleep and being more prone to infectious disease.
Read Full Post >
Whooping Cough is a highly contagious disease and according to health officials, has reached “epidemic levels” in the state of Washington.
By the end of March, that state had 640 cases compared to 94 last year at this time. At this rate, it could put Washington “on pace to have the highest number of recorded cases in decades,” according to the health department’s press release.
So far, there are no reported deaths. The last reported death from whooping cough was in 2011, where two people died.
The highly contagious disease is preventable through a series of vaccines. It is recommended children begin receiving the series as early as 2 months old and finish the round by the age of four or six years of age. Once the initial series of shots are completed, a child does not need to receive the booster shot until they are at least 11 years old. It is recommended to receive the booster every 10 years after that during adulthood.
A recent study that researched the outbreak in California in 2010 found that immunized children between eight and 12 years old were more likely to catch the bacterial disease than kids of other ages. This suggests the childhood vaccine wears off as kids get older.
Read Full Post >
Gardasil, the vaccine used for preventing HPV that can cause cervical cancer and genital warts is now approved for boys.
Gardasil was initially marketed for girls age 9 to 26 to protect against 4 strains of HPV, or the human papillomavirus. HPV is contracted by engaging in any sort of sexual activity. There are currently at least 100 known HPV viruses but this vaccine targets types 6, 11, 16 and 18: 16 and 18 are targeted against cervical cancer, and 6 and 11 aganist genital warts. The vaccine was originally approved in June of 2006 and since has been approved for additional indications including vaccination against vaginal and anal cancers.
Gardasil received approval for prevention of genital warts for boys and men in October of 2009 and approval against anal warts and prevention of anal cancer in October of 2011. The vaccine does give boys and men immunity to HPV type 16 and 18 that cause cervical cancer. Obviously, men cannot contract cervical cancer, but they can pass the strains of HPV to their female partners unwittingly. Men and women can both be carriers of these viruses so having both genders vaccinated is essential to reduce the virus from spreading.
Read Full Post >